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Abstract
Background: Coronary heart disease (CHD) incidence has declined significantly in the US, as have levels of major coronary
risk factors, including LDL-cholesterol, hypertension and smoking, but whether trends in subclinical atherosclerosis mirror
these trends is not known.
Methods and Findings: To describe recent secular trends in subclinical atherosclerosis as measured by serial evaluations of
coronary artery calcification (CAC) prevalence in a population over 10 years, we measured CAC using computed
tomography (CT) and CHD risk factors in five serial cross-sectional samples of men and women from four race/ethnic
groups, aged 55–84 and without clinical cardiovascular disease, who were members of Multi-Ethnic Study of Atherosclerosis
(MESA) cohort from 2000 to 2012. Sample sizes ranged from 1062 to 4837. After adjusting for age, gender, and CT scanner,
the prevalence of CAC increased across exams among African Americans, whose prevalence of CAC was 52.4% in 2000–02,
50.4% in 2003–04, 60.0% is 2005–06, 57.4% in 2007–08, and 61.3% in 2010–12 (p for trend ,0.001). The trend was strongest
among African Americans aged 55–64 [prevalence ratio for 2010–12 vs. 2000–02, 1.59 (95% confidence interval 1.06, 2.39);
p = 0.005 for trend across exams]. There were no consistent trends in any other ethnic group. Risk factors generally
improved in the cohort, and adjustment for risk factors did not change trends in CAC prevalence.
Conclusions: There was a significant secular trend towards increased prevalence of CAC over 10 years among African
Americans and no change in three other ethnic groups. Trends did not reflect concurrent general improvement in risk
factors. The trend towards a higher prevalence of CAC in African Americans suggests that CHD risk in this population is not
improving relative to other groups.
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Introduction
Coronary heart disease mortality (CHD) has declined by more
than 50% in the United States in the past four decades [1,2], and
the incidence [3] and prevalence [4] of CHD have also
significantly declined in recent years. National trends in smoking,
lipid levels [5], and hypertension control [6] have been favorable
during this period, although rates of obesity and diabetes have
risen5. The aggregate impact of these risk factor trends on
atherosclerosis and risk for CHD is unclear. Data on subclinical
atherosclerosis are not monitored, and it is not known if they
mirror trends in CHD morbidity and mortality. Subclinical disease
trends could inform our understanding of the relative impact of
prevention and treatment and of the composite impact of CHD
risk factors on CHD risk as well as help predict future clinical
disease burden at the population level.
Coronary artery calcification (CAC) is a specific marker for
atherosclerosis7 that reflects the extent of atherosclerotic plaque8, 9
and predicts CHD risk10, 11. Thus, the prevalence and extent of
CAC would be expected to track with the burden of subclinical
atherosclerotic disease and serve as an indicator of population risk
for CHD events.
We examined the prevalence of CAC in five serial cross-
sectional samples of men and women each aged 55–84 years from
the cohort of the Multi-Ethnic Study of Atherosclerosis who were
examined over a 10-year period. More specifically, we compared
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55–84 year olds in 2000–02 to 55–84 year olds at four additional
time points up to 2010–2012 (see Figure 1). Our hypotheses were
that (1) the prevalence of CAC would decline over 10 years and (2)
differences in risk factor levels and medication usage, particularly
lipid-lowering therapy, would largely explain any decline ob-
served.
Methods
Design, Setting, and Participants
Details of the study design have been published elsewhere [7].
In brief, between July 2000 and August 2002, 6,814 men and
women who identified themselves as either White, African-
American, Hispanic, or Chinese and were 45 to 84 years old
and free of clinically apparent cardiovascular disease, were
recruited from portions of six U.S. communities: Baltimore City
and Baltimore County, MD; Chicago, IL; Forsyth County, NC;
Los Angeles County, CA; Northern Manhattan and the Bronx,
NY; and St. Paul, MN. Each field site recruited from locally
available sources, including lists of residents, lists of dwellings, and
telephone exchanges. In the last few months of the recruitment
period, supplemental sources included lists of Medicare beneficia-
ries from the Centers for Medicare and Medicaid Services and
referrals by participants to ensure adequate numbers of minorities
and elderly subjects. The study was approved by the institutional
review boards at all participating centers, including the Johns
Hopkins University School of Medicine Joint Committee on
Clinical Investigation, Harbor-UCLA Research and Education
Institute Human Subjects Committee, University of Vermont
Committees on Human Research, University of Minnesota
Human Research Protection Program, UCLA Office of Human
Research Protection Program, Northwestern University Social and
Behavioral Sciences Institutional Review Board, University of
Washington Human Subjects Division, Wake Forest University
Health Sciences Office of Research Institutional Review Board,
and Columbia University Medical Center Institutional Review
Board, and all participants gave written informed consent.
Participants were invited back for 4 subsequent examinations.
Approximately half of the returning cohort had repeat CT scans
during 2002–03, with the other half scanned during 2004–05,
approximately 25% were rescanned during 2007–08, and ,70%
were selected for rescanning during 2010–12 based on prior
participation in a substudy [8]. Participants were not selected for
rescanning based on any clinical characteristics and were thus
treated as random samples.
We included participants aged 55–84 at each exam who had a
CT scan, excluding those who had reported having had
cardiovascular disease prior to the exam. Persons with atrial
fibrillation were also excluded.
CT scanning
Computed tomography scanning of the chest was performed
using either ECG-triggered (at 80% of the RR interval) electron-
beam computed tomography scanner (Chicago, Los Angeles, and
New York Field Centers) (Imatron C-150, Imatron, San Francisco)
or using prospectively ECG- triggered scan acquisition at 50% of
the RR interval with a multi-detector computed tomography
system acquiring four simultaneous 2.5 mm slices for each cardiac
cycle in a sequential or axial scan mode (Baltimore, Forsyth
County and St. Paul Field Centers) (Lightspeed, General Electric,
Waukesha, WI or Siemens, Volume Zoom, Erlangen, Germany).
During a study, each participant was scanned twice except during
Exam 5, when each participant received one cardiac scan. Scans
were read centrally at the Harbor-University of California, Los
Angeles Research and Education Institute, to identify and quantify
coronary calcification. Calcium scores among scanning centers
and between participants were adjusted using a standard calcium
phantom scanned simultaneously with the participant. The
average Agatston score was used in all analyses [9]. The presence
of calcification was defined as an Agatston score .0 on any scan.
Agreement regarding presence of coronary calcification was high
(Kappa statistic 0.90 to 0.93 between and within readers), and the
intraclass correlation coefficient for the Agatston score between
readers was 0.99 [9].
Figure 1. Participant selection. Participants whose ages fell between 55 and 84 years were selected from each examination. Note that many of
the same individuals were thus included in multiple analyses but treated as if there were independent cross-sectional samples. Adjustment for age
and use of robust standard errors were used to control for age and account for individuals being used multiple times in the analysis.
doi:10.1371/journal.pone.0094916.g001
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Assessment of Risk Factors
At each examination, standardized questionnaires were used to
obtain information about level of education, annual household
income, smoking history and medication usage for high blood
pressure, high cholesterol or diabetes. Smoking was defined as
current, former, or never. Height and weight were measured with
light clothing and without shoes. Body mass index (BMI) was
calculated as weight in kilograms divided by height in meters
squared. Resting blood pressure was measured three times in the
seated position using a Dinamap model Pro 100 automated
oscillometric sphygmomanometer (Critikon, Tampa, FL). The
average of the last two measurements was used in analysis.
Hypertension was defined as systolic pressure greater than or equal
to 140 mm Hg, diastolic pressure greater than or equal to 90 mm
Hg or current use of anti-hypertensive medication. Total and
HDL cholesterol, triglycerides, and glucose were measured from
blood samples obtained after a 12-hour fast. LDL-cholesterol was
calculated using the Friedewald equation. Diabetes was defined as
fasting glucose greater than 6.99 mmol/L (126 mg/dl) or current
use of hypoglycemic medication. We calculated a Framingham
Risk Score (FRS) for CHD for each participant [10].
Statistical Analysis
We examined risk factor levels and prevalence at each exam but
for simplicity report levels at baseline and year 10, as they reflect
overall trends. The prevalence of CAC at each exam was
estimated using the following cutpoints of the Agatston score,
after adjusting for age, gender, ethnicity, and scanner: 0 vs. .0
and 0, 1–99, 100–299, and 300 or higher. We compared the
prevalence of having any CAC using prevalence rate regression,
adjusting for the distribution of age, gender, and scanner type from
the baseline exam. The goal at each exam was to create
comparable samples by applying the same exclusion criteria that
were used for entry into MESA. Some participants ‘‘age in’’ at
later exams (those who were younger than 55 at baseline), and
some participants ‘‘age out’’ at later exams once they become 85
or older. Some participants are included in multiple exams;
however, we were not interested in modeling change over time for
particular participants. Cluster-robust standard errors were used to
account for the fact that some participants will appear in multiple
subsets. This allows for the fact that multiple observations from the
same participant are not independent. Such dependence would
not impact the coefficients/prevalence ratios, but would result in
underestimated standard errors. The cluster-robust standard
errors deal with this issue, with observations within a participant
assumed to be correlated, and observations from different
participants independent.
Differences in trends by ethnic group were noted, and further
analyses were stratified by ethnicity. Additionally, we constructed a
model that controlled for the use of lipid-lowering therapy,
cholesterol levels, anti-hypertensive therapy, blood pressure levels,
and smoking. We added an exam-by-lipid-lowering therapy
interaction term and also applied the fully-adjusted model to
participants who were not currently taking lipid-lowering medi-
cation. We examined models that included only non-overlapping
samples (excluding those aged 60–69). Finally, analyses were
stratified by age group and gender to determine if trends were
similar among age and gender subgroups. Tests for trends in CAC
prevalence over time were performed for each model.
Results
There were 4837 and 2532 participants included at baseline
and year 10, respectively, who were aged 55–84, without a history
of cardiovascular disease and had complete data for analysis
(Table 1). The mean age was 67.1 years at baseline and 68.0 years
at year 10. The gender and ethnic distributions were similar. The
proportion who did not complete high school was lower at year 10.
The prevalence of current smoking was lower, while the
prevalence of former smoking was higher. Average systolic and
diastolic blood pressures were lower by 8.0 mmHg and
3.0 mmHg, respectively, while the proportion with hypertension
increased from 52.9% to 55.6%, due to increased use of
antihypertensive medication. Total cholesterol decreased
8.0 mg/dl, HDL-cholesterol increased by 4.4 mg/dl, and the
proportion of participants who reported taking lipid-lowering
medication increased from 19.7% to 35.0%. The prevalence of
diabetes increased from 14.6% to 17.9%, although mean body
mass index was only 0.4 units higher. The FRS decreased from
9.1% to 7.4%. The proportion with CAC increased from 60.0% to
65.8% (p,0.0001). Trends in risk factors and FRS were consistent
across the ethnic groups (Table S1).
Of the 8 groups of scanners employed in the study over 10
years, one scanner used only during the first three exams was
Table 1. Characteristics of the Cohorts at Baseline and Exam




Number 4837 2532 —
Age (yrs) 67.16 7.5 68.0 6 8.1 ,0.001
Gender (% male) 2291 (47.4) 1183 (46.7) 0.53
Race/ethnicity (%) 0.46
White 1887 (39.0) 974 (38.5)
African American 1343 (27.8) 684 (27.0)
Hispanic 1030 (21.3) 553 (21.8)
Chinese 577 (11.9) 321 (12.7)
Education ,high school (%) 994 (20.5) 342 (13.5) ,0.001
Smoking status (%) ,0.001
current 518 (10.7) 210 (8.3)
former 1908 (39.4) 1158 (45.7)
never 2411 (49.8) 1164 (46.0)
Systolic BP (mmHg) 131.0 6 21.8 123.0 6 20.3 ,0.001
Diastolic BP (mmHg) 71.96 10.2 68.9 6 9.9 ,0.001
Anti-hypertensive medications (%) 2126 (44.0) 1288 (50.9) ,0.001
Hypertension (%) 2561 (52.9) 1408 (55.6) 0.015
Total cholesterol (mg/dl) 194.0 6 35.6 186.0 6 36.0 ,0.001
HDL Cholesterol (mg/dl) 51.56 15.1 55.9+/16.7 ,0.001
Lipid lowering medications (%) 953 (19.7) 886 (35.0) ,0.001
Body Mass Index (kg/m2) 28.2 6 5.3 28.66 5.5 0.001
Diabetes (%) 708 (14.6) 454 (17.9) ,0.001
FRS (10-year risk, %) 12.8 (9.1) 10.1(7.4) ,0.001
Prevalence of CAC (%) 2904 (60.0) 1665 (65.8) ,0.001
Data are mean 6 standard deviations or number (%). P-values are based on
regression models (linear or logistic) with cluster-robust standard errors.
BP = blood pressure; FRS = Framingham Risk Score; CAC= coronary artery
calcification.
doi:10.1371/journal.pone.0094916.t001
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associated with a 5.5% higher prevalence of CAC (p= 0.008) (data
not shown).
After adjusting for age, gender, ethnicity, and scanner, the
proportion of participants with no CAC decreased over time from
40.7% to 32.6% (p= 0.007), and the proportions with a CAC
score 1–99 increased from 29.9% to 37.0% (p= 0.01), with a CAC
score of 100–299 increased from 14.7% to 17.7% (p= 0.14), and
with CAC score 400 or over decreased from 9.1% to 7.2%
(p= 0.11) (Figure 2). Comparing Exam 5 (2010–12) to baseline
(2000–02) the adjusted prevalence ratio for CAC .0 was 1.08
(p,0.001 for trend).
Trends in CAC among the four race/ethnic groups revealed a
significant trend towards increased prevalence of CAC in African
Americans but not in any other group (Table 2); the p-value for a
differences in trends in African Americans compared to the other
groups after adjusting for all other variables was 0.049. Among
African Americans, the CAC prevalence ratio (year 10 vs.
baseline) was 1.27 (p,0.001 for test for trend). Adjustment for
risk factors made no notable difference in CAC trends in any
ethnic group. Similar trends were found when the definition of
CAC prevalence was changed from an Agatston score .0 to an
Agatston score .10 (Table S2).
Trends towards higher CAC prevalence were further concen-
trated among younger African Americans (Table 3). Adjusted
prevalence ratios were 1.67 among African Americans aged 55–64
(p = 0.005 for trend across exams), 1.39 among African Americans
aged 65–74, and 0.92 among African Americans aged 75–84
(p = 0.54 for trend across exams). Only among Chinese aged 65–
74 was there a similar and significant, but more modest trend,
towards increased CAC: prevalence ratio 1.12 (p= 0.03 for trend
across exams).
There were no significant differences in these trends by gender
(data not shown). Excluding data obtained from the scanner
associated with higher CAC, restricting the analysis to those not on
lipid-lowering medications, and excluding participants aged 55–74
at baseline who would otherwise be included at both baseline and
Year 10 did not affect findings (data not shown).
Discussion
We found secular trends towards a higher prevalence of CAC
over a 10-year period among African American men and women
who did not have clinical cardiovascular disease, particularly
among those aged 55–74 years. We found no consistent,
statistically significant trends in any other ethnic group. This
finding was contrary to our hypothesis that the secular trends in
CAC would parallel recent downward trends in cardiovascular
mortality and incidence, and it was not consistent with the
concomitant improvement in Framingham Risk Score. However,
it may be consistent with evidence of differential trends in CHD
risk by ethnicity. For example, the proportion of Americans with at
least one of three major coronary risk factors decreased
significantly between 1999–2000 and 2009–2010 in the National
Health and Nutrition Examination Surveys among non-Hispanic
white and Mexican-American adults but not among non-Hispanic
blacks [11]. Also, the Atherosclerosis Risk in Communities Study
found steeper declines in incidence of myocardial infarction in
whites than African Americans between 1987 and 2008 [12]. We
explored several explanations for these trends, including increased
sensitivity of CT scanners time, use of statin therapy, which might
artifactually increase CAC scores, and an increase in the
prevalence of diabetes. However, none of these explanations
appears to explain the increase in African Americans or to modify
the trend in any other group.
Coronary calcification is a specific marker for atherosclerosis
[13–15], although it is not sensitive to non-calcified plaque, and its
presence may represent other, non-atherosclerotic processes [16].
Still, because of its close pathologic ties to atherosclerotic plaque
and its ability to predict cardiovascular events [17,18], it may be
considered a marker of both individual and population risk of
cardiovascular disease, particularly CHD. The trend towards an
increased prevalence of CAC among African Americans is
Figure 2. Adjusted prevalence of CAC at different levels among those aged 55–84 across exams, Multi-Ethnic Study of
Atherosclerosis. Adjusted to the average baseline age (67 years), gender (47% male), race/ethnicity (39% white, 28% African American, 21%
Hispanic, and 12% Chinese), and scanner (electron-beam CT vs. other).
doi:10.1371/journal.pone.0094916.g002
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Table 2. Prevalence of CAC.0 at baseline and Year 10 and relative prevalence of CAC.0 across exams among those aged 55–84
years without cardiovascular disease, 2000–02 through 2010–12, by ethnicity, Multi-Ethnic Study of Atherosclerosis.
Exam White African American Hispanic Chinese
Baseline CAC prevalence 67.50% 52.20% 56.60% 59.80%
Year 10 CAC prevalence 71.50% 61.30% 62.40% 63.90%
Adjusted for age, gender, and scanner Baseline Ref 95% CI Ref 95% CI Ref 95% CI Ref 95% CI
2 1.00 [0.97,1.04] 0.96 [0.91,1.02] 1.02 [0.96,1.08] 1.00 [0.93,1.08]
3 1.02 [0.98,1.06] 1.14 [1.07,1.22] 1.09 [1.00,1.18] 1.01 [0.93,1.09]
4 1.03 [0.96,1.10] 1.14 [1.04,1.26] 1.11 [1.00,1.24] 0.97 [0.85,1.11]
5 1.01 [0.92,1.11] 1.27 [1.11,1.47] 1.14 [0.97,1.34] 1.06 [0.98,1.15]
p-value for trend 0.64 0.001 0.15 0.73
Adjusted for age, gender, education,
scanner, and risk factors
Baseline Ref 95% CI Ref 95% CI Ref 95% CI Ref 95% CI
2 1.01 [0.97,1.04] 0.99 [0.93,1.05] 1.00 [0.95,1.06] 1.00 [0.92,1.08]
3 1.01 [0.97,1.05] 1.13 [1.06,1.21] 1.09 [1.00,1.18] 1.03 [0.95,1.11]
4 1.03 [0.97,1.10] 1.15 [1.04,1.26] 1.11 [1.00,1.23] 0.97 [0.85,1.11]
5 1.01 [0.92,1.11] 1.26 [1.10,1.44] 1.11 [0.95,1.29] 1.06 [0.97,1.16]
p-value for trend 0.67 0.001 0.24 0.94
Risk factors included total and HDL cholesterol, lipid-lowering medication, systolic blood pressure, anti-hypertensive medication, presence of diabetes, and smoking
status (current, former, never). The p-value testing for differences in trends was p = 0.10 adjusting for age, gender and scanner, and p= 0.14 adjusting for age, gender,
scanner, and risk factors. Tests for differences in trends in African Americans compared to the other three groups was p = 0.029 and p= 0.049 respectively.
doi:10.1371/journal.pone.0094916.t002
Table 3. Prevalence of CAC.0 at baseline and Year 10 and relative prevalence of CAC.0 across exams among those aged 55–84
years without cardiovascular disease, 2000–02 through 2010–12, by ethnicity, Multi-Ethnic Study of Atherosclerosis.
Exam White African American Hispanic Chinese
Baseline CAC prevalence 51.30% 37.40% 41.50% 48.20%
Age 55–64 Baseline Ref [95% CI] Ref [95% CI] Ref [95% CI] Ref [95% CI]
2 1.06 [0.97,1.16] 1.03 [0.89,1.18] 1.00 [0.87,1.15] 1.08 [0.91,1.30]
3 1.08 [0.99,1.18] 1.26 [1.07,1.48] 1.23 [1.00,1.51] 0.88 [0.70,1.10]
4 1.10 [0.95,1.27] 1.51 [1.18,1.93] 1.26 [0.93,1.70] 0.76 [0.47,1.25]
5 1.13 [0.88,1.45] 1.67 [1.10,2.51] 1.10 [0.73,1.66] 0.96 [0.77,1.19]
p-value for trend 0.16 0.005 0.85 0.08
Baseline CAC prevalence 72.10% 54.00% 62.30% 63.60%
Age 65–74 Baseline Ref [95% CI] Ref [95% CI] Ref [95% CI] Ref [95% CI]
2 1.01 [0.96,1.07] 0.97 [0.87,1.07] 1.02 [0.94,1.12] 0.97 [0.85,1.10]
3 0.98 [0.91,1.05] 1.20 [1.08,1.33] 1.09 [0.96,1.24] 1.1 [0.98,1.24]
4 0.99 [0.89,1.09] 1.08 [0.92,1.28] 1.13 [0.95,1.35] 1.17 [0.97,1.41]
5 0.88 [0.77,1.01] 1.39 [1.11,1.74] 1.19 [0.92,1.53] 1.12 [0.95,1.31]
p-value for trend 0.1 0.005 0.19 0.03
Baseline CAC prevalence 87.70% 78.30% 77.60% 73.60%
Age 75–84 Baseline Ref [95% CI] Ref [95% CI] Ref [95% CI] Ref [95% CI]
2 0.98 [0.93,1.03] 1.00 [0.92,1.09] 0.98 [0.89,1.07] 1.03 [0.91,1.17]
3 0.98 [0.93,1.03] 1.00 [0.90,1.11] 1.05 [0.92,1.21] 1.07 [0.95,1.22]
4 1.02 [0.91,1.14] 1.05 [0.92,1.20] 1.06 [0.92,1.23] 1.02 [0.84,1.22]
5 1.08 [0.94,1.25] 0.92 [0.75,1.13] 1.09 [0.88,1.34] 1.15 [1.00,1.32]
p-value for trend 0.31 0.54 0.48 0.63
Adjusted for age, gender, education, scanner, and risk factors, including total and HDL cholesterol, lipid-lowering medication, systolic blood pressure, anti-hypertensive
medication, presence of diabetes, and smoking status (current, former, never).
doi:10.1371/journal.pone.0094916.t003
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consistent with other data suggesting that the favorable trends in
CHD experienced in the general population is not being paralleled
in this group [11,12]. _ENREF_10
We used a longitudinal cohort study to assess secular trends, a
method that has been employed in previous population-based
longitudinal studies [19–21]. We found trends in risk factors that
are similar to trends using more conventional independent cross-
sectional samples, such as from NHANES [5]. This includes
declines in smoking [22], systolic and diastolic blood pressure, total
cholesterol [23], and increases in HDL-cholesterol [23], the use of
antihypertensive medication [6], use of lipid-lowering medication,
body mass index [22], and diabetes. Lower socioeconomic status
has been associated with higher CAC prevalence [24] though not
consistently [25]. However, adjustment for trends in these
variables did not alter the trend in CAC in any group.
Our study has several limitations. The main limitation is that
our sampling design attempted to replicate independent serial
cross-sectional samples by our sampling design and statistical
adjustments, but we may not have completely eliminated selection
bias stemming from participation in a longitudinal study. For
example, the significant decrease in the proportion with no more
than high school education serves as an indication that less well
educated participants tended not to return and were therefore less
well represented groups after baseline. We adjusted for education
and other potential confounders to mitigate against these potential
biases. In addition, the samples were not necessarily representative
of the US population and, in particular, could not include in-
migration of groups that would be expected to affect population
risk. We assumed that this effect would be small. Finally, the
samples were not independent; however, we did also account for
this in the statistical analysis, including an analysis of participants
who did not overlap between baseline and year 10.
African Americans, the group that displayed a significant trend
towards a higher prevalence of CAC, also had the lowest CAC
prevalence at baseline, raising the question of whether this group
had a higher ‘‘ceiling’’ than the others, with more opportunity to
experience an upward trend. We do not believe that the secular
trends would differ based on initial CAC prevalence, particularly
given that no group was close to zero prevalence or 100%
prevalence, and therefore, with no opportunity to decrease or
increase, respectively, but it remains a possible explanation for the
differences observed among the ethnic groups.
The changes in CT scanner technology over the 10 years could
have contributed artifact to trends in CAC. The study began using
three types of scanners in six centers; over 10 years, 12 different
scanners were employed. While the same scoring system was used
over time, and scores were adjusted using a calcium phantom, the
potential exists that newer models of scanners tended to identify
more calcification. We did determine that one scanner was
associated with a higher prevalence of CAC, but this did not
explain the trends because it was used only during the first 3
exams, its use was not predominant among sites with African
Americans, and excluding this scanner did not change the
observed trends in CAC.
Another factor that could have potentially modified CAC
prevalence was the dramatic increase in the use of statins. Statins
lower serum LDL-cholesterol and have been shown to be
associated with lower fibrofatty plaque volume [26] and regression
of atherosclerosis [27] and either no change [28] or even an
increase in the relative amount of calcium, [29] a phenomenon
posited to be due to an increase in the concentration of calcium
within plaques. (Statins comprised 93–95% of the lipid-lowering
medications used across the exams in MESA.) In a recent study of
patients who received either pitavastatin or pravastatin, intravas-
cular ultrasound measurements for 119 patients before and after 8
months of treatment showed significant increases in the amount of
calcium imaged – from 0.42 to 0.55 mm 3/mm and 0.44 to
0.55 mm 3/mm, respectively, for two statin treatments [29]. The
Agatston score is created using a step function that gives increasing
weight to foci with greater Hounsfield units, and it is thus possible
that plaques with denser lesions due to statin therapy could have
higher Agatston scores.
A final limitation of note is our inability to confirm the trends in
CAC prevalence with trends in CHD incidence due to limited
follow-up duration, specifically for the latter years of the study.
The concentration of a trend towards increased CAC among
African Americans aged 55–64 and, to a lesser extent, aged 65–74,
is notable. While cardiovascular risk factors have generally
improved in this population and in the general population, obesity
and diabetes have increased. Diabetes is strongly associated with
CAC [30,31]_ENREF_25 and with increased CHD risk [32,33].
However, the African Americans in this cohort, including among
those aged 55–64, in whom CAC trends were strongest, did not
exhibit stronger trends toward obesity and diabetes than other
groups (see Table S1). At baseline in MESA, and in most other
studies comparing ethnic groups, African Americans have a
significantly lower prevalence of CAC than whites [25]. Despite
these trends, the relative ranking of prevalence of CAC after 10
years among the four ethnic groups remained the same, with
African Americans having the lowest, and whites having the
highest prevalence.
The trends in CAC were unrelated to trends in CHD risk
factors over ten years; thus, CAC prevalence may not be a good
indicator of ten year temporal changes in CHD risk in a
population. Because coronary atherosclerosis is known to initiate
in early in life and progress over the decades of early adult life,
CAC likely represents lifelong cumulative exposure to risk factors,
and thus changes in exposure to risk factors over a relatively short
period (10 years, in this case) may not significantly affect CAC
prevalence or the presence of coronary atherosclerosis.
In summary, we found an increasing prevalence of CAC over a
10-year period among middle-aged African Americans, but not in
whites, Hispanics, or Chinese with no history of clinical
cardiovascular disease. Trends in CAC were unrelated to trends
in risk factors over this period.
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